The latest price target for Kymera Therapeutics (NASDAQ:KYMR) was reported by Stephens & Co. on November 18, 2024. The analyst firm set a price target for $65.00 expecting KYMR to rise to within 12 months (a possible 53.27% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Kymera Therapeutics (NASDAQ:KYMR) was provided by Stephens & Co., and Kymera Therapeutics initiated their overweight rating.

The last upgrade for Kymera Therapeutics Inc happened on August 26, 2024 when Wolfe Research raised their price target to $65. Wolfe Research previously had a peer perform for Kymera Therapeutics Inc.

The last downgrade for Kymera Therapeutics Inc happened on January 3, 2024 when B of A Securities changed their price target from $45 to $30 for Kymera Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kymera Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kymera Therapeutics was filed on November 18, 2024 so you should expect the next rating to be made available sometime around November 18, 2025.

While ratings are subjective and will change, the latest Kymera Therapeutics (KYMR) rating was a initiated with a price target of $0.00 to $65.00. The current price Kymera Therapeutics (KYMR) is trading at is $42.41, which is within the analyst’s predicted range.